Retroviral insertional mutagenesis preferentially identifies oncogenes rather than tumor suppressor (TS) genes, presumably because a single retroviral-induced mutation is sufficient to activate an oncogene and initiate a tumor, whereas two mutations are needed to inactivate a TS gene. Here we show that TS genes can be identified by insertional mutagenesis when the screens are performed in Blm-deficient backgrounds. Blm-deficient mice, like Bloom syndrome patients, have increased frequencies of mitotic recombination owing to a mutation in the RecQ proteinlike-3 helicase gene. This increased mitotic recombination increases the likelihood that an insertional mutation in one allele of a TS gene will become homozygoused by nonsister chromatid exchange and the homozygosity of the insertion provides a marker for identifying the TS gene. We also show that known as well as novel TS genes can be identified by insertional mutagenesis in Blm-deficient mice and identify two JmjC family proteins that contribute to genome stability in species as evolutionarily diverse as mammals and Caenorhabditis elegans.
Introduction
To establish a genetic background in which homozygous mutations can be easily recovered, Luo et al (2000) generated ES cells and mice that were homozygous for a hypomorphic mutation (McDaniel et al, 2003) in the Bloom syndrome (BLM) RecQ protein-like-3 DNA helicase gene, Blm tm3Brd (subsequently referred to as Blm m3 ) (Ellis et al, 1995) . This was important as two previous studies showed that Blm-null mutations are embryonic lethal (Chester et al, 1998; Goss et al, 2002) . BLM is a recessive human genetic disorder associated with genomic instability (German, 1993) . Helicases unwind double-stranded DNA, a process required for various aspects of DNA metabolism, including transcription, DNA repair, and replication. BLM predisposes patients to a wide variety of malignancies, which implies that the BLM helicase is required for maintaining genomic stability in many cell types. BLM genomic instability is unique in that it is characterized by increased mitotic recombination (German, 1993) and non-sister chromatid exchange (Luo et al, 2000) . Mitotic recombination between non-sister chromatids that are heterozygous for a mutation of tumor suppressor (TS) gene can produce daughter cells that have lost the wild-type allele and are now homozygous for the mutant allele (Adams and Bradley, 2002) . This increased ability to homozygous TS mutations is the reason that BLM patients and Blm
m3
-deficient mice are thought to develop a higher frequency of cancer.
The rate of loss of heterozygosity (LOH) in Blm
-deficient ES cells is 4.2 Â10 À4 events per locus per cell per generation (Luo et al, 2000) , which is elevated 18-fold compared to wildtype ES cells. Guo et al (2004) have exploited this increased LOH to generate a genome-wide library of homozygous mutant ES cells from heterozygous mutant cells produced by infection of Blm m3 -deficient ES cells with a gene trap retrovirus. They showed that they could use this library to identify bi-allelic gene trap mutations in novel mismatch repair genes. Likewise, Yusa et al (2004) treated Blm tm1Khor -deficient ES cells with N-ethyl-N-nitrosourea (ENU) and identified bi-allelic chemically induced mutations in genes required for glycosylphosphatidylinositol (GPI)-anchor biosynthesis. These studies showed that it is possible to perform phenotype-based recessive screens in Blm-deficient ES cells.
The Blm m3 allele has also been shown to increase the number of intestinal polyps in Apc heterozygous mutant mice (Luo et al, 2000; Goss et al, 2002) . As Blm m3 -deficient mice have elevated rates of mitotic recombination, this suggested that increased polyp numbers might result from increased non-sister chromatid exchange and subsequent loss of the wild-type Apc allele. Microsatellite mapping of polyp DNA confirmed this hypothesis and showed that Apc TS mutations are homozygoused at increased frequencies in Blm m3 -deficient mice.
Here, we have asked whether retroviral insertional mutagenesis in Blm m3 -deficient mice could be used as a tool for identifying TS genes. We reasoned that if a retrovirus integrated into the coding region of one allele of a TS gene, and interfered with its expression such as by splicing into viral sequences followed by transcription termination in the viral long terminal repeat (LTR), this integration might be homozygoused at an increased frequency in Blm
-deficient mice owing to the increased frequency of non-sister chromatid exchange and we could use this homozygosity as a marker for identifying TS genes. Here we show that viral-induced TS mutations do become homozygoused in Blm m3 -deficient mice and this homozygosity can be used as a marker for identifying TS genes.
Results

Reduced tumor latency in AKXD-Blm m3/m3 mice
To determine whether insertional mutagenesis in Blm-deficient mice can be used as a tool for identifying TS genes, we crossed the Blm m3 mutation (Luo et al, 2000) onto the AKXD-10, -14, and -27 inbred strain backgrounds by three successive rounds of backcross mating ( Figure 1A ). These three strains were derived from an F 2 cross of AKR/J and DBA/2J mice (Gilbert et al, 1993) . Each strain inherited B50% of its genome from AKR/J and B50% from DBA/2J mice, although the relative contribution to each strain differs due to random assortment during the inbreeding process. All three strains develop a high frequency of retrovirally induced B-cell lymphomas, which is caused by the expression of endogenous murine leukemia viruses that are transmitted in these strains (Gilbert et al, 1993) . N 3 backcross Blm þ /m3 mice were then intercrossed and the Blm þ / þ and Blm m3/m3 progeny aged for tumors. While these mice were aging, the Blm m3 mutation was backcrossed three more times to each of the three AKXD strains and the N 6 Blm þ / þ and Blm m3/m3 progeny also aged for tumors ( Figure 1A ). We then aged and monitored 181 N 3 and 72 N 6 mice for the development of tumors. Blm m3/m3 animals died significantly earlier than Blm þ / þ animals when all of the data for the N 3 and N 6 generations were combined ( Figure 1B ). AKXD-Blm m3/m3 mice had an average lifespan of 400.9710.7 days, whereas AKXD-Blm þ / þ mice had an average lifespan of 448.7710.9 days. Similar results were observed when the individual strains were analyzed separately, with the exception of the AKXD-27-Blm þ / þ and AKXD-27-Blm m3/m3 mice, where there was less difference in survival (data not shown).
Common integration sites in AKXD lymphomas
Next, 1023 retroviral integration sites from AKXD-Blm m3/m3 lymphomas, and 515 retroviral integration sites from AKXDBlm þ / þ lymphomas, were cloned and sequenced following inverse polymerase chain reaction (PCR) (Li et al, 1999) . All sequencing data are deposited in the Retroviral Tagged Cancer Gene Database (RTCGD) (http://rtcgd.ncifcrf.gov) and can be viewed on-line. Most integration sites could be positioned in the mouse genome by BLAST searches. Interestingly, nearly 44% of the integrations (674) were located at common integration sites (CISs) (Supplementary Table 1 ). CISs are regions in the genome that are targets of retroviral integration in two or more tumors and are thus more likely to contain a cancer gene (Suzuki et al, 2002) . In total, 218 CISs were identified in the screen (Supplementary In all, 60 CIS genes are orthologs or homologs of genes mutated in human cancer, whereas the rest have not yet been examined for a role in cancer. These are the most interesting since these are the genes that represent potential novel human cancer genes. The majority of genes found in AKXD lymphomas fall into classes commonly associated with cancer (Supplementary Table 1 
Candidate TS genes
To determine whether integrations in the coding region of TS genes in Blm m3 -deficient tumors are homozygoused and can be used as a marker to identify TS genes, we first looked for CIS genes that were specific to Blm m3/m3 lymphomas and whose coding regions were consistently disrupted by viral integration. In total, 17 CISs genes met these criteria ( Table I ). For six of these genes, there is published evidence that they are TS genes. Rbl1 and Rbl2 are homologues of Rb1, a well-known TS gene. Mice lacking Rbl1 exhibit a myeloproliferative disorder characterized by ectopic myeloid hyperplasia in the spleen and liver (LeCouter et al, 1998) . Likewise, Rbl2 is located in a region of homology with human 16q12.2 where deletions have been found in several human neoplasms, including breast, ovarian, hepatic and prostate cancers (Yeung et al, 1993) . In addition, mice carrying loss-offunction mutations in Rb and Rbl1 or Rb and Rbl2 are highly cancer prone, indicating that in a variety of tissues, Rbl1 and Rbl2 suppress tumor development induced by loss of Rb and are functionally redundant with Rb (Dannenberg et al, 2004) . Cdkn2c is a cyclin-dependent kinase inhibitor that controls cell cycle G1 progression. Cdkn2c knockout mice develop spontaneous pituitary tumors and lymphomas late in life and treatment of these mice with a chemical carcinogen induces tumors at an accelerated rate (Bai et al, 2003) . Fanconi anemia, complementation group G (FANCG) mutations induce diverse clinical symptoms including developmental abnormalities, bone marrow failure, and early occurrence of malignancies. Primary splenocytes, bone marrow progenitor cells, and embryonic fibroblasts from Fancg knockout mice also exhibit increased chromosomal breakage and sensitivity to mitomycin C (Yang et al, 2001 ). Tnfrsf6 plays a central role in the regulation of programmed cell death. Tnfrsf6 mutant mice develop lymphadenopathy and a lupus-like disease. In addition, TNFRSF6 mutations have been observed in nasal natural killer/T-cell lymphomas and burn scar-related squamous cell carcinomas (Lee et al, 2000) . E2f3 functions downstream of Rb and plays a crucial role in cell cycle control. Disruption of E2f3 promotes the development of metastatic medullary thyroid carcinomas in Rb1 þ /À mutant mice (Ziebold et al, 2003) . As viral integration into the coding region of a CIS can induce the expression of truncated proteins that function as oncogenes, we expected that at least some of the genes listed in Table I function as oncogenes rather than TS genes. This was in fact the case as at least two of the genes listed in Table I are oncogenes. Prdm16 is a myeloid leukemia oncogene that is activated in t(1;3)(p36;q21)-positive leukemia cells (Mochizuki et al, 2000) . This translocation induces the expression of a short form of PRDM16 that lacks the PR domain. The PR domain is common to a subset of zinc-finger proteins that function as negative regulators of tumorigenesis. It is also related to the SET domain found in genes that regulate chromatin structure, such as MLL. The lack of a PR domain could therefore inactive the chromatin-associated functions of a protein without affecting its other functions. Viral integrations in Prdm16 also promote the expression of a truncated protein that lacks the PR domain (Du et al, 2005) . Prdm1 is related to Prdm16 and also contains a PR domain. Viral integrations in the coding regions of Prdm1 are therefore also likely to be selected because they too induce the expression of a protein that lacks the PR domain.
Viral integrations into TS genes undergo LOH
To determine whether any of the integrations listed in Table I have become homozygoused in tumors, control brain and tumor DNAs were analyzed by Southern analysis using probes specific for each locus. The wild-type and virally rearranged mutant alleles were then quantitated using a luminescent image analyzer. If duplication of the viral allele did not occur following viral integration, the wild-type allele should be equal or more intense than the mutant allele as the lymphomas are always contaminated with normal tissue. If, however, duplication of the viral allele occurred, the wild-type allele, representing only contaminating normal tissue, will be less intense than the mutant allele in tumors where there is not much contaminating normal tissue. Representative Southern results for the six genes listed in Table I predicted to encode TS genes are shown in Supplementary Figure 1A and the quantitated results in Figure 2A . In all cases, the mutant allele was more intense than the wild-type allele consistent with duplication of the viral allele. In addition, integrations at two other genes listed in Table I , C330016O10Rik and Pou2f2, also showed evidence of LOH (Supplementary Figure 1A , Figure 2A ). As expected, integrations at Prdm1 and Prdm16 did not become duplicated following viral integration (Supplementary Figure 1B , Figure 2B ) nor did the integrations in any of the other genes listed in Table I (data not shown). C330016O10Rik is the mouse ortholog of human NEDD4-binding protein 3 (N4BP3). This FEZ1 domain-containing gene is related to the FEZ1/LZTS1 leucine zipper, putative tumor suppressor-1. Pou2f2 is a POU domain transcription factor that controls the expansion and/or maintenance of mature B cells (Schubart et al, 2001) .
Another CIS gene, Fbxl10, also showed evidence of LOH (Supplementary Figure 2A , Figure 2C ). Viral integrations in the coding sequence of Fbxl10 were identified in two Blmdeficient lymphomas, but in a third tumor, the viral integration was located in the first coding exon and did not disrupt the coding region of Fbxl10. Thus, Fbxl10 was not included in Table I . Fbxl10 is a member of the jumonji family of proteins (Balciunas and Ronne, 2000) . A Caenorhabditis elegans homolog of Fbxl10, T26A5.5, has been identified in an RNA interference (RNAi) screen designed to detect mutator genes that contribute to genome stability in C. elegans somatic cells (Pothof et al, 2003) . These genes protect the C. elegans genome against insertions and deletions and are therefore excellent candidates for TS genes in higher eukaryotes.
We also examined two CIS genes that were mutated exclusively in Blm m3 -deficient lymphomas, Hivep3 and Jmjd5, in which the viral integrations were located in intronic sequences but upstream of the first coding exon (Supplementary Table 1 ). In both cases, the viral integrations appeared to be duplicated in tumors (Supplementary Figure  2A , Figure 2C ). These viral integrations are therefore predicted to block rather than upregulate gene expression, which was confirmed by Northern analysis (see below). Hivep3 is a member of the human immunodeficiency virus type 1 enhancer-binding protein (HIVEP) family. HIVEPs are large zinc-finger proteins that regulate transcription through the kappa-B enhancer motif. Antisense or dominant-negative HIVEP3 enhances NF-kappa-B-dependent transactivation and JNK phosphorylation and inhibits apoptosis and cytokine gene expression (Oukka et al, 2002) . Interestingly, Jmjd5 is also a JmjC family protein, and a C. elegans homolog of Jmjd5, C06H2.3, was identified in the same RNAi-based mutator screen used to identify T26A5.5 (Pothof et al, 2003) . Therefore, Jmjd5 is also an excellent candidate for a TS gene.
As a control, we analyzed two CIS genes, Rfx5 and Crb2, that were identified in Blm m3 -deficient tumors but whose coding regions were not disrupted by viral integration. In both cases, the wild-type allele was more intense than the virally induced mutant allele (Supplementary Figure 2B , Figure 2D ), consistent with the expectation that these are oncogenes.
In another control, we checked to see whether any CIS genes were consistently disrupted by viral integration in AKXD-Blm þ / þ tumors. Only one gene, Psma5, was identified (Supplementary Table 1 ). Psma5 encodes the alpha-type 5 subunit of the proteasome and is an unlikely candidate for a TS gene. Consistent with this, viral integrations at Psma5 did not show evidence of LOH (data not shown). In contrast, 17 CIS genes were disrupted by viral integration in AKXDBlm m3/m3 tumors and eight of them showed evidence of LOH (Table I ). The Blm mutation therefore appears to increase the frequency at which TS genes can be identified by insertional mutagenesis and can be used as a marker to identify TS genes.
Reduced TS gene expression in tumors
A total of 11 CIS genes including Fbxl10, Hivep3, Jmjd5 and the eight CIS genes listed in Table I that showed LOH met our criteria for a TS gene. To confirm their expression was reduced in lymphomas as expected for a TS gene, we Figure 3A and quantitated in Figure 3B . Expression results for the other TS genes (with the exception of Pou2f2 which could not be detected by Northern analysis) are shown in Supplementary Figure 3A and quantitated in Supplementary Figure 3B . In all cases examined, expression was reduced in tumors by 80% or more compared to tumors without integrations at the CIS. These results further confirm that these are TS genes.
Fbxl10 and Jmjd5 are mutator genes
Based on the C. elegans studies, we decided to determine whether Fbxl10 and Jmjd5 are mutator genes. To do this, we established an RNAi-based system for suppressing their expression in eukaryotic cells and then measured the effect of this suppression on genome stability. Six retroviral vectors expressing small hairpin RNAs (shRNAs) were constructed for each gene and introduced into NIH 3T3 cells. Infected cells were then selected for their puromycin resistance and the expression levels of each gene quantitated by Northern analysis (Supplementary Figure 4) . Two shRNA-expressing constructs for each gene were used for suppression studies so that off-target effects of the shRNAs could be avoided. Next, we developed an assay that could be used to determine whether cells that expressed these shRNAs exhibited defects in genome stability. For this a slippage vector was constructed ( Figure 4A ). This vector contains 17 CA-dinucleotide repeats cloned just downstream from the initiation codon of the enhanced green fluorescent protein (eGFP) gene, which puts the eGFP-coding sequence out of frame. Instability resulting in gains of one or loss of two CA repeats, for example, will restore the reading frame and activate eGFP ( Figure 4A ). The slippage vector was then introduced into NIH3T3 cells and stable cell lines were established. The reporter cells were then infected with shRNA-expressing retroviruses and stably infected cells selected with puromycin. Single cell clones were then expanded for 2 weeks and eGFP-positive cells counted using a fluorescence-activated cell sorter (FACS). Luria-Delbruck fluctuation analyses (Luria and Delbruck, 1943) were then used to calculate the mutation rate. The mutation rate for control cells expressing an shRNA for the luciferase gene was 7 Â10
À7 events per cell per Control  11680  4295  Control  7338  12739  Control  7221  13847  Control  4301  8610  Control  4149  11978  Control  4313  7105  7088 3134 Figure 2 Quantitative analysis of retroviral integrations in tumor DNAs of AKXD-Blm m3 mice. Southern blots of genomic tumor DNAs were performed using flanking probes for each CIS gene. Tumor ID numbers are shown at the top of each column. A tumor that does not have a viral integration at that locus was used for the control. Gel images were acquired using a luminescent image analyzer and the band intensities quantified using the Image Gauge ver.4 software. The ratio of the intensity of the wild-type band (light gray) and mutant band (dark gray) is shown for each tumor sample. Among the CIS genes whose coding regions were consistently disrupted by viral integration, some of the genes (A) showed evidence of bi-allelic integration, but others (B) did not. (C) Bi-allelic integrations were also detected for three other CIS genes whose expressions were downregulated by viral integration, (D) but was not detected in CIS genes whose expressions may be upregulated by viral integration in AKXD-Blm þ / þ lymphomas. Figure 4B , column 1). Empty vector-infected cells also showed a similar mutation rate (data not shown) as did cells infected with retroviruses that expressed shRNAs that did not inhibit Jmjd5 and Fbxl10 expression ( Figure 4B , columns 2 and 3, respectively). In contrast, infection with two retroviruses that reduced Jmjd5 expression 14 and 26% produced mutation rates that were five and three times higher than control cells, respectively ( Figure 4B , columns 4 and 5). Similarly, infection with two retroviruses that reduced Fbxl10 expression 19 and 40% produced mutation rates that were about three times higher than control cells ( Figure 4B , columns 6 and 7). As a positive control, we examined the mutation rate of cells expressing shRNAs for Msh6 and Msh2, two well-known mismatch repair genes. Theses cells showed seven and 17 times higher mutation rates than control cells, respectively (data not shown). Thus, we conclude that suppression of Jmjd5 and Fbxl10 confers a mutator phenotype to the cells. To determine whether Jmjd5 and Fbxl10 might function in DNA mismatch repair similar to Msh2, we examined the survival of cells with downregulated Jmjd5 and Fbxl10 expression after exposure to N-methyl-N 0 -nitro-N-niotrosoguanidine (MNNG). MNNG cytotoxicity is caused by its ability to introduce O 6 -methylguanine (O 6 -meG) into DNA (Karran and Bignami, 1996) . It can direct misincorporation of thymine during replication, generating O 6 -meG:T mismatches. Recognition of these mismatches by the mismatch repair system leads to cell cycle arrest and apoptosis. Cells defective in mismatch repair are resistant to killing by MNNG. This effect has been called tolerance (Karran and Bignami, 1994) . NIH3T3 cells infected with shRNA-expressing retroviruses were treated with a range of MNNG concentrations. After 10-14 days of culture, surviving colonies were counted. In control experiments, cells were infected with shRNA retroviruses that failed to downregulate Jmjd5 and Fbxl10 and as expected they had the same sensitivities as control cells. In contrast, cells expressing Msh2 shRNA that downregulated Msh2 expression 17% were more resistant to MNNG than control cells ( Figure 5 ). Similarly, among cells expressing Jmjd5 shRNA that downregulated Jmjd5 expression, 14% were more resistant to MNNG than control cells, although the increase of tolerance was not as large as with Msh2 shRNA. These results suggest that Jmjd5, like Msh2, might also function in DNA mismatch repair. The same effect was not seen, however with Fbxl10 shRNA. Cells expressing Fbxl10 shRNA that downregulated Fbxl10 expression 19% did not increase MNNG tolerance. Although we cannot exclude the possibility that the level of suppression we were able to achieve was too low to have an effect in the MNNG assay, it is possible that Fbxl10 might function in DNA repair processes other than mismatch repair.
Discussion
Here, we show that TS genes can be identified by insertional mutagenesis when the screens are performed in Blm m3 -deficient mice. TS genes were identified as CIS genes whose expression is disrupted by viral integration and the viral integrations are homozygoused in Blm m3 -deficient tumors. Homozygosity was determined by Southern analysis due to the fact that these tumors were produced on partially inbred strain backgrounds. While this did not allow us to prove unambiguously that homozygosity resulted from non-sister chromatid exchange, this is by far the most likely mechanism. Homozygosity was never detected in control lymphomas from wild-type (Blm þ / þ ) animals and heterozygous Apc mutations have previously been shown to be homozygoused by non-sister chromatid exchange in intestinal tumors in Apc þ /À Blm m3/m3 mice (Luo et al, 2000) . Of the 11 genes we identified that met our criteria for a TS gene, there is published evidence that six are TS genes. These include the two Rb1 homologues, Rbl1 (p107) and Rbl2 (p130); the cyclin-dependent kinase inhibitor Cdkn2c; the Fanconi anemia complementation group Fancg gene; the FAS antigen Tnfrsf6 gene and E2f3. Not surprisingly, none of these genes has been previously identified in insertional mutagenesis screens performed in wild-type mice. In addition, we identified five novel candidate TS genes. These include the mouse ortholog of human NEDD4-binding protein 3 C330016O10Rik; the POU domain transcription factor Pou2f2; the human immunodeficiency virus type 1 enhancerbinding protein Hivep3 and two JmjC domain-containing genes Fbxl10 and Jmjd5. Interestingly, these two JmjC family genes have C. elegans homologs that were recently identified in an RNAi-based mutator screen designed to identify genes that protect the C. elegans genome against insertions and deletions (Pothof et al, 2003) . Using a similar RNAi-based mutator screen in mammalian cells, we confirmed that these genes also protect the mammalian genome against insertions and deletions. Both genes are therefore excellent candidates for TS genes in mammalian cells.
Surprisingly, two of the novel candidate TS genes we identified are mutated by viral integration in wild-type lymphomas. Two viral integrations in Pou2f2 have been identified in AKXD lymphomas wild type at Blm (Suzuki et al, 2002) . Likewise, two viral integrations have been identified in lymphomas isolated from Cd3-deficient mice (Bijl et al, 2005) . The Pou2f2 integrations identified in Blm m3 -deficient lymphomas are located in intron 1 (three integrations) or in exon 1 (one integration) ( Table I ). In all eight cases, the integrations are predicted to disrupt the Pou2f2-coding region. Similarly, one integration in Fbxl10 intron 12 has been identified in a wild-type AKXD lymphoma and another integration in intron 12 was identified in a BXH-2 leukemia (Li et al, 1999; Suzuki et al, 2002 ). An integration in Fbxl10 intron 2 was similarly identified in a p27
Kip1 þ /À lymphoma (Hwang et al, 2002) . This is in addition to the three integrations we identified in Blm m3 -deficient lymphomas. All these six integrations disrupt the Fbxl10-coding region (five integrations) or result in decreased Fbxl10 expression (one integration). While the reason for this is unclear, one possibility is that these genes function as haploinsufficient TS genes in wild-type lymphomas but in Blm m3 -deficient tumors there is selective pressure to inactive the wild-type allele.
Our studies show that TS genes can be identified by insertional mutagenesis in Blm m3 -deficient mice. However, even in Blm m3 -deficient mice, there are still more oncogenes than TS genes identified by insertional mutagenesis (Supplementary Table 1 ). This was expected as the retrovirus that induces disease in AKXD mice has very strong enhancers and promoters, which can efficiently activate the expression of an oncogene when it lands nearby even in Blm m3 -deficient lymphomas. In order to inactivate a TS gene, the virus must first integrate into the coding region and then be homozygoused by LOH or the other allele inactivated by another mechanism. While the rate of loss of heterozygosity in Blm m3 -deficient ES cells is elevated 18-fold compared to wild-ype ES cells, the overall rate is still only 4.2 Â10 and Msh2 (open square). As controls, cells were infected with retroviruses expressing luciferase shRNA (closed square) or shRNAs that did not inhibit Jmjd5 and Fbxl10 expression (closed circle by shRNA-A4 and closed triangle by shRNA-B1, respectively). These cells were exposed to increasing amounts of MNNG for 1 h in the presence of O 6 -benzylguanine. After 10-14 days, surviving colonies were counted. The experiments were repeated 10 times and the average survival rates were shown. mutation is hypomorphic and chromosome instability and tumor predisposition is inversely correlated with BLM protein levels (McDaniel et al, 2003) , it might be possible to increase the number of TS genes identified by insertional mutagenesis by performing these screens in Blm null mice. However, as the Blm null mutation is lethal (Chester et al, 1998; Goss et al, 2002) , this would require the generation of a Blm conditional allele or the use of compound heterozygotes that carry a null allele on one chromosome and a Blm m3 allele on the other (McDaniel et al, 2003) . One could of course also weaken or delete the promoters or enhancers carried by the virus so it would be less likely to activate an oncogene. However, this would also cripple the ability of the virus to replicate and induce tumors. Alternatively, one could use another insertional mutagen, such as the transposon Sleeping Beauty, which can be built to lack promoter/enhancer activity and function solely as a gene trap (Dupuy et al, 2005) .
Several laboratories have recently shown that the JmjC domain we identified in two of our novel candidate TS genes is the signature motif for the long sought after histone demethylase . There are over 100 JmjC domain-containing proteins across the evolutionary phyla and essentially all of them are predicted to be enzymes (Clissold and Ponting, 2001 ). The JmjC domain-containing proteins FBXL10 and FBXL11 (renamed JHDM1B and JHDM1A, respectively) have been shown to demethylate di-and monomethylated H3-K36 to mono-or unmethylated products , the JMJD2 subfamily has been shown to demethylate trimethylated H3-K9 to di-and monomethylated products (Whetstine et al, 2006) , whereas JHDM2A has been shown to demethylate mono-and dimethyl-H3-K9 to mono-and unmethylated products (Yamane et al, 2006) . JHDM2A also exhibits hormone recruitment to androgen-receptor target genes resulting in H3-K9 demethylation and transcriptional activation. This links histone demethylation to hormone-dependent transcriptional activation (Yamane et al, 2006) . Whetstine et al (2006) have shown that RNAi depletion of the C. elegans homologue of JMJD2A also increases general H3-K9 trimethylation and localizes H3-K36 trimethylation levels on meiotic chromosomes, triggering p53-dependent germline apoptosis. In the C. elegans germ line, DNA damage-induced apoptosis, but not physiological apoptosis, requires the functional p53 homolog, CEP-1. JMJD2A-induced apoptosis was shown to be abrogated in a cep-1 deletion mutant, suggesting a link between JMJD2A inactivation and DNA damage-induced apoptosis. As seen previously in cells undergoing DNA damage-induced apoptosis, increased numbers of RAD-51 foci were also observed in the nucleus at mid-pachytene. RAD-51 is a member of the highly conserved RecA protein family involved in strand invasion/exchange during double strain break (DSB) repair. Increased RAD-51 foci levels may therefore reflect an increase in the levels of DSBs or a delay in the progression of meiotic DSB repair.
While it remains to be determined exactly how loss-offunction mutations in Fbxl10 and Jmjd5 cause cancer, the findings of Whetstine suggest that imbalances in histone demethylation brought about by loss of Fbxl10 might affect DNA repair either through increased DSBs or delayed repair of DSBs. Our studies suggest that loss of Jmjd5 might also produce defects in mismatch repair. In addition, histone methylation has been implicated in multiple other biological processes including heterochromatin formation, X-inactivation, genomic imprinting, and silencing of homeotic genes (reviewed in Martin and Zhang, 2005) . Loss of Fbxl10 and Jmjd5 are therefore likely to produce a myriad of effects in the cell and might not be limited to the repair of DNA mismatches and DSBs.
Among histone modifications, acetylation has been unambiguously associated with cancer (Santos-Rosa and Caldas, 2005) . Histone acetyltransferases such as PCAF, P300, CBP, and MOZ are rearranged or mutated in several human cancers, acting as TS genes. Histone deacetylases (HDACs) are also frequently overexpressed in human cancer, suggesting that they function as oncogenes. However, a clear correlation between histone methylation and cancer has not been conclusively demonstrated, although some histone methyltransferase genes including MLL1, MLL2, SMYD3, and EZH2 have been shown to be amplified and/or overexpressed in human cancer. In this study, we have provided evidence that two JmjC domain-containing proteins, Fbxl10 and Jmjd5, are TS genes in hematopoietic cancer. Our findings suggest that both histone methylases and demethylases may play important roles in cancer. Identification of JmjC proteins as protein demethylases provides a unique opportunity to explore the relationship between this rapidly growing family of histonemodifying enzymes and cancer.
Materials and methods
Mice and tumor classification AKXD-10, -14, and -27 mice develop a high incidence of B-cell lymphomas (Gilbert et al, 1993) . These mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and aged in our colony at the National Cancer Institute, Frederick. Mice carrying the Blm tm3Brd mutation (Luo et al, 2000) were kindly provided by Alan Bradley (The Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK). The Blm tm3Brd mutation was crossed onto the three AKXD strain backgrounds as described in the Results. The mice were then aged and observed for the onset of lymphomas. Moribund mice were examined by histopathological analysis and the lymphomas immunostained with CD45R and CD3 antibodies, which are specific for B and T cells, respectively.
Inverse PCR cloning and DNA sequencing
Inverse PCR was performed as described with slight modifications (Suzuki et al, 2002) . Briefly, 5 mg tumor DNA was digested to completion with SacII, BamHI, SacI, and XbaI (Takara, Japan). Digested-DNA was then self-circularized by dilution and ligation using T4 DNA ligase (2450 U; Takara, Japan) in a total volume of 600 ml at 161C for 16 h. Circular DNA was then precipitated with ethanol and dissolved in 40 ml TE buffer. In total, 2 ml was used in the primary PCR in a 50 ml PCR reaction volume containing 20 nmol each dNTP, 10 pmol each forward and reverse primer, 1 Â buffer 2 and 2.5 U enzyme mix using the Expand Long Template PCR System (Roche, USA). We used a GeneAmp PCR System 9700 (Applied Biosystems, USA) programmed at 941C for 2 min, followed by 30 cycles of 941C for 20 s, 601C for 40 s, 681C for 12 min and a final extension step at 681C for 7 min. The primary PCR product was then quantitated following electrophoresis on 1% agarose genes and 0.1-1.0 ml of the primary PCR product used as the template in the secondary PCR reaction. The secondary PCR was carried out using the same conditions as the primary PCR, except that secondary amplification primers were used. We separated the secondary PCR product on a 1% agarose gel, purified it using the QIAquick Gel Extraction Kit (Qiagen, USA) and directly cloned it using a Perfectly Blunt Cloning Kit (Novagen, Germany). The primer sequences for inverse PCR have been described (Li et al, 1999) . DNA sequencing was performed using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, USA) on an ABI PRISM 3100-Avant Genetic Analyzer (Applied Biosystems, USA) using SP6 and T7 sequencing primers.
Sequence comparisons
We compared the retroviral integration site (RIS) sequences against the public mouse genome database, August 2005 draft assembly (http://genome.ucsc.edu/) and identified annotated candidate genes located near each RIS. We compared these RISs with previously identified RISs in the web-accessible Mouse Retroviral Tagged Cancer Gene Database (http://genome2.ncifcrf.gov/ RTCGD). To define common integrations sites, we used the conditions described previously (Suzuki et al, 2002) .
Southern and Northern blotting
High-molecular weight genomic DNAs were prepared from frozen tissues (tumors and control brains) as described previously (Jenkins et al, 1982) . Restriction enzyme-digested DNAs (5 mg) were electrophoresed in 0.8% agarose gels and transferred to positively charged nylon membranes (Roche, USA) followed by UV crosslinking. The probes were labeled with Gene Images Alkphos Direct Labeling (Amersham, USA) and the bands detected using CDP-Star reagents (Roche). For Northern blotting, total RNAs from the tumors were extracted with Trizol solution (Invitrogen, USA). A 10 mg aliquot of total RNA was separated on a 1.0% agarose gel containing 2% formaldehyde and transferred onto a nylon membrane. The probes were labeled with DIG (digoxigenin) DNA Labeling Mix (Roche) by the PCR and used for hybridization. The blot was treated with anti-DIG antibody conjugated with alkaline phosphatase (Roche) and then developed with CDP-Star reagents. The gel images were acquired with a luminescent image analyzer LAS-3000 (Fujifilm, Japan). The intensities of the bands were quantified using Image Gauge ver.4 software (Fujifilm, Japan).
Production of the retroviruses expressing shRNAs
To downregulate expression of candidate TS genes, we cloned complementary oligonucleotides for each gene into the RNAi-ready pSIREN-RetroQ vector (BD Clontech, USA). Two complimentary oligonucleotides for each siRNA target site were synthesized according to the manufacturer's protocol and cloned into the pSIREN-RetroQ vector. The expression vector was then transfected into the virus-packaging cell line Plat E (a kind gift from Dr Toshio Kitamura, University of Tokyo), using the Genejuice transfection reagent (Novagen, Germany). Virus-containing supernatants were collected 48 h after transfection. For infection, 1 Â10 5 NIH 3T3 cells were plated in 60 mm dishes and cultured for 6 h with viruscontaining supernatants (5 Â10 5 colony-forming unit (CFU)/ml as assessed by puromycin resistance in NIH 3T3 cells) in the presence of 6 mg/ml polybrene (Sigma). Cells were then washed with PBS, incubated for 24 h with Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, and then exposed to selection in medium containing 1 mg/ml puromycin (Sigma). shRNA constructs that suppressed best were identified by Northern analysis of infected cells following drug selection or 2 weeks.
Quantitative analysis for mutator (mismatch repair) activity
For the construction of the slippage-eGFP vector, the eGFP-coding sequence with a mutated initiation codon (ATG to CTG) was generated by PCR. A new initiation codon that leads to out of frame eGFP expression was supplied with the oligonucleotides containing CA repeats shown below and cloned into the BamHI and NotI site of pEGFP-N1 (BD Clontech, USA), replacing the wild-type eGFPcoding sequence. The oligonucleotides containing CA repeats were synthesized as follows: EcoRI-initiation-(CA)17, (5 0 -AATTCCGC CATGGAA(CA)17G) and BamHI-(CA)17, (5 0 -GATCC(TG)17TTC CATGGCGG). The annealed oligonucleotides were then ligated into the EcoRI and BamHI site of the modified pEGFP-N1 vector to create the slippage-eGFP vector. The vector was then linearized by ApaL1 digestion and transfected into NIH3T3 cells using the Genejuice transfection reagent (Novagen, Germany). Transfected cells were subsequently exposed to selection in medium containing 500 mg/ml G418 (Nakarai, Japan), and the drug-resistant colonies picked after 10 days of selection. Cell lines stably expressing the slip-eGFP transcripts were selected by Northern blot. The slip-eGFP NIH3T3 cells were then infected with each shRNA-expressing retrovirus as described above, and selected with puromycin. The puromycin-resistance cell clones were then expanded and the eGFPpositive cells detected by a FACS (Calibur, BD, USA). Similar experiments were done at least six times and the data subjected to Luria-Delbruck fluctuation analyses (Luria and Delbruck, 1943) .
MNNG sensitivity
Survival after MNNG treatment was determined by clonogenic assay. NIH3T3 cells were infected with shRNA-expressing retroviruses and selected with puromycin. The resistant cells at clonal density (100 cells/35 mm dish) were treated 18 h after seeding with MNNG (WAKO chemicals, Japan). The treatments were performed by removing media from cells and by adding serum-free media. MNNG was then added to the indicated final concentration. After 1 h of drug exposure, the cells were rinsed extensively with PBS, and fed on complete growth media. After 10-14 days, surviving colonies were fixed with PBS containing 2% paraformaldehyde, stained with Giemsa solution and counted. During the whole procedure from 2 h before drug exposure, O 6 -benzylguanine (20 mM; Sigma, USA) was included in the media to inhibit endogenous methyltransferase activity that might otherwise remove the methyl groups added by MNNG (Dolan et al, 1990) .
Supplementary data
Supplementary data are available at The EMBO Journal Online.
